Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROMETHEUS BIOSCIENCES, INC.

(RXDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Prometheus Biosciences, Inc.(NasdaqGS:RXDX) added to S&P Global BMI Index

09/20/2021 | 12:00am EDT

Prometheus Biosciences, Inc.(NasdaqGS:RXDX) added to S&P Global BMI Index


© S&P Capital IQ 2021
All news about PROMETHEUS BIOSCIENCES, INC.
10/12PROMETHEUS BIOSCIENCES : to Present at Jefferies Virtual Next Generation IBD Therapeutics ..
AQ
10/05PROMETHEUS BIOSCIENCES : Oppenheimer Starts Prometheus Biosciences at Outperform With $35 ..
MT
09/20PROMETHEUS BIOSCIENCES, INC.(NASDAQG : RXDX) added to S&P Global BMI Index
CI
09/0827,254,280 Common Stock of Prometheus Biosciences, Inc. are subject to a Lock-Up Agreem..
CI
09/08Certain Stock Options of Prometheus Biosciences, Inc. are subject to a Lock-Up Agreemen..
CI
09/08Certain Warrants of Prometheus Biosciences, Inc. are subject to a Lock-Up Agreement End..
CI
08/23PROMETHEUS BIOSCIENCES : Expands CEO and President Mark McKenna's Role - Adds Chairmanship..
MT
08/23PROMETHEUS BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
08/23Prometheus Biosciences, Inc. Announces Board Changes
CI
08/11PROMETHEUS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and R..
AQ
More news
Analyst Recommendations on PROMETHEUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,64 M - -
Net income 2021 -78,3 M - -
Net cash 2021 253 M - -
P/E ratio 2021 -11,2x
Yield 2021 -
Capitalization 1 011 M 1 011 M -
EV / Sales 2021 461x
EV / Sales 2022 479x
Nbr of Employees 26
Free-Float 65,1%
Chart PROMETHEUS BIOSCIENCES, INC.
Duration : Period :
Prometheus Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMETHEUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 26,03 $
Average target price 34,75 $
Spread / Average Target 33,5%
EPS Revisions
Managers and Directors
Mark C. Mckenna Chairman, President & Chief Executive Officer
Keith W. Marshall Chief Financial Officer & Treasurer
Laurens Kruidenier Chief Scientific Officer
Olivier Laurent Chief Technology Officer
Mark Stenhouse Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
PROMETHEUS BIOSCIENCES, INC.0.00%1 011
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455